*Members of the D:A:D Study Group are listed in the Appendix.
The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study
Article first published online: 30 MAR 2006
Volume 7, Issue 4, pages 218–230, May 2006
How to Cite
Law, M., Friis-Møller, N., El-Sadr, W., Weber, R., Reiss, P., D'Arminio Monforte, A., Thiébaut, R., Morfeldt, L., De Wit, S., Pradier, C., Calvo, G., Kirk, O., Sabin, C., Phillips, A., Lundgren, J. and for the D:A:D Study Group (2006), The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Medicine, 7: 218–230. doi: 10.1111/j.1468-1293.2006.00362.x
- Issue published online: 30 MAR 2006
- Article first published online: 30 MAR 2006
- Received: 14 April 2005, accepted 23 August 2005
- antiretroviral therapy;
- Framingham risk equation;
- myocardial infarction
The D:A:D (Data Collection on Adverse Events of Anti-HIV Drugs) Study, a prospective observational study on a cohort of 23 468 patients with HIV infection, indicated that the incidence of myocardial infarction (MI) increased by 26% per year of exposure to combination antiretroviral treatment (CART). However, it remains unclear whether the observed increase in the rate of MI in this population can be attributed to changes in conventional cardiovascular risk factors.
To compare the number of MIs observed among participants in the D:A:D Study with the number predicted by assuming that conventional cardiovascular risk equations apply to patients with HIV infection.
The Framingham equation, a conventional cardiovascular risk algorithm, was applied to individual patient data in the D:A:D Study to predict rates of MI by duration of CART. A series of sensitivity analyses were performed to assess the effect of model and data assumptions. Predictions were extrapolated to provide 10-year risk estimates, and various scenarios were modelled to assess the expected effect of different interventions.
In patients receiving CART, the observed numbers of MIs during D:A:D follow up were similar to or somewhat higher than predicted numbers: 9 observed vs 5.5 events predicted, 14 vs 9.8, 22 vs 14.9, 31 vs 23.2 and 47 vs 37.0 for<1 year, 1–2 years, 2–3 years, 3–4 years and >4 years CART exposure, respectively. In patients who had not received CART, the observed number of MIs was fewer than predicted (3 observed vs 7.6 predicted). Nine per cent of the study population have a predicted 10-year risk of MI above 10%, a level usually associated with initiation of intervention on risk factors.
A consistent feature of all analyses was that observed and predicted rates of MI increased in a parallel fashion with increased CART duration, suggesting that the observed increase in risk of MI may at least in part be explained by CART-induced changes in conventional risk factors. These findings provide guidance in terms of choosing lifestyle or therapeutic interventions to decrease those risk factors in much the same way as in persons without HIV infection.